Welsh, DEet al. Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness.
Psychiatr Serv 2007;58:864–867.
Sweeney, JK.Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805–811.
Pope, M.Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.
Am J Psychiatry 2002;159:1927–1929.
Marder, SRet al. Dose response of prophylactic antipsychotics.
J Clin Psychiatry 1993; 54(Suppl.):24–30.
5.Schooler, NR.Relapse and rehospitalization: comparing oral and depot antipsychotics.
J Clin Psychiatry 2003;64(Suppl. 16):14–17.
Dencker, SJet al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64:226–237.
Silverstone, T.Depot antipsychotics in bipolar affective disorder.
Int Clin Psychopharmacol 1993;8:119–122.
Cookson, J.Depot antipsychotics in the prophylaxis of bipolar affective disorder.
Br J Psychiatry 1994;165:827–829.
McElroy, SLet al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702–709.
Lyons, Bet al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.
Br J Psychiatry 2005;187:229–234.
Mullen, Jet al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.
J Clin Psychiatry 2005;66:111–121.
12.Keck, PE Jr,
Tourkodimitris, Set al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
Am J Psychiatry 2003;160:1651–1658.
13.Keck, PE Jr,
Potkin, Set al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Am J Psychiatry 2003;160:741–748.
Calabrese, Jet al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. [erratum appears in Arch Gen Psychiatry. 2004 Feb;61(2):176]. Arch Gen Psychiatry 2003;60:1079–1088.
Keck, PE Jr,
Macfadden, Wet al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
Am J Psychiatry 2005;162:1351–1360.
Lindenmayer, JPet al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
Am J Psychiatry 2003;160:1125–1132.
Karcher, Ket al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
J Clin Psychiatry 2003;64:1250–1257.
Meyer, DA.A rating scale for mania: reliability, validity and sensitivity.
Br J Psychiatry 1978;133:429–435.
Asberg, M.A new depression scale designed to be sensitive to change.
Br J Psychiatry 1979;134:382–389.
20.Guy, W.Clinical global impressions scale. In: New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: US National Institutes of Mental Health, 1976: 218–222.
Angus, JW.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–19.
22.Barnes, TR.A rating scale for drug-induced akathisia.
Br J Psychiatry 1989;154:672–676.
23.Guy, W.Abnormal involuntary movement scale. In: New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: US National Institutes of Mental Health, 1976: 534–537.
24.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC, American Psychiatric Association, 2000.
Ades, J.Traduction et utilisation de l’echelle de Simpson et Angus de symptomes extra-pyramidaux.
Benjamin, S.How to examine patients using the abnormal involuntary movement scale.
Hosp Community Psychiatry 1988;39:1172–1177.
Lasser, RAet al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.
Schizophr Res 2005;77:119–128.
28.Keck, PE Jr,
West, SA.Compliance with maintenance treatment in bipolar disorder.
Psychopharmacol Bull 1997;33:87–91.
Scott, J.Treatment non-adherence in affective disorders.
Acta Psychiatr Scand 2002;105:164–172.
Naylor, GJet al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients.
Br J Psychiatry 1986;148:723–725.
Binder, CE.A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.
Acta Psychiatr Scand Suppl 2007;434:50–56.
Preskorn, SH.Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap.
J Clin Psychiatry 2007;68(Suppl. 7):27–33.
Kujawa, Met al. A new psychosocial tool for gaining patient understanding and acceptance of long-acting injectable antipsychotic therapy. Psychiatry (Edgemont) 2009;6:22–27.
Haskins, JTet al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
Bipolar Disord 2009;11:827–839.
Schaffer, Aet al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225–255.